TG THERAPEUTICS INC (TGTX)
US88322Q1085 - Common Stock
We assign a fundamental rating of 5 out of 10 to TGTX. TGTX was compared to 588 industry peers in the Biotechnology industry. Both the profitability and the financial health of TGTX get a neutral evaluation. Nothing too spectacular is happening here. TGTX shows excellent growth, but is valued quite expensive already. With these ratings, TGTX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
TGTX had positive earnings in the past year.
TGTX had a negative operating cash flow in the past year.
In the past 5 years TGTX reported 4 times negative net income.
TGTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.85%, TGTX belongs to the top of the industry, outperforming 95.72% of the companies in the same industry.
TGTX has a Return On Equity of 7.90%. This is amongst the best in the industry. TGTX outperforms 95.89% of its industry peers.
TGTX has a better Return On Invested Capital (5.90%) than 95.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 7.9% | ||
| ROIC | 5.9% |
ROA(3y)-63.44%
ROA(5y)-68.2%
ROE(3y)-159.11%
ROE(5y)-195.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of TGTX (5.43%) is better than 95.38% of its industry peers.
TGTX's Operating Margin of 8.82% is amongst the best of the industry. TGTX outperforms 95.38% of its industry peers.
With an excellent Gross Margin value of 93.94%, TGTX belongs to the best of the industry, outperforming 95.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.82% | ||
| PM (TTM) | 5.43% | ||
| GM | 93.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TGTX is destroying value.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
TGTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TGTX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.07 indicates that TGTX is not in any danger for bankruptcy at the moment.
TGTX has a Altman-Z score of 3.07. This is in the better half of the industry: TGTX outperforms 76.37% of its industry peers.
A Debt/Equity ratio of 0.62 indicates that TGTX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.62, TGTX is not doing good in the industry: 74.14% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.07 |
ROIC/WACC0.64
WACC9.29%
2.3 Liquidity
A Current Ratio of 5.92 indicates that TGTX has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.92, TGTX is doing good in the industry, outperforming 61.99% of the companies in the same industry.
A Quick Ratio of 5.18 indicates that TGTX has no problem at all paying its short term obligations.
With a Quick ratio value of 5.18, TGTX perfoms like the industry average, outperforming 56.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.92 | ||
| Quick Ratio | 5.18 |
3. Growth
3.1 Past
TGTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.68%, which is quite impressive.
TGTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 8245.39%.
Measured over the past years, TGTX shows a very strong growth in Revenue. The Revenue has been growing by 335.01% on average per year.
EPS 1Y (TTM)100.68%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q74.36%
Revenue 1Y (TTM)8245.39%
Revenue growth 3Y1059.22%
Revenue growth 5Y335.01%
Revenue growth Q2Q43871%
3.2 Future
Based on estimates for the next years, TGTX will show a very strong growth in Earnings Per Share. The EPS will grow by 246.33% on average per year.
TGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.52% yearly.
EPS Next Y-1222%
EPS Next 2Y596.58%
EPS Next 3Y400.07%
EPS Next 5Y246.33%
Revenue Next Year14.17%
Revenue Next 2Y33.63%
Revenue Next 3Y36.81%
Revenue Next 5Y42.52%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
TGTX is valuated quite expensively with a Price/Earnings ratio of 1347.00.
Based on the Price/Earnings ratio, TGTX is valued cheaply inside the industry as 94.01% of the companies are valued more expensively.
TGTX is valuated expensively when we compare the Price/Earnings ratio to 24.92, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for TGTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1347 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TGTX is valued cheaper than 94.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 91.52 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TGTX's earnings are expected to grow with 400.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y596.58%
EPS Next 3Y400.07%
5. Dividend
5.1 Amount
TGTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TG THERAPEUTICS INC
NASDAQ:TGTX (4/26/2024, 7:19:24 PM)
After market: 13.57 +0.1 (+0.74%)13.47
-0.44 (-3.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.08B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1347 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 7.9% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 8.82% | ||
| PM (TTM) | 5.43% | ||
| GM | 93.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.92 | ||
| Quick Ratio | 5.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)100.68%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-1222%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8245.39%
Revenue growth 3Y1059.22%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y